Further studies on the interaction of nonpolyglutamatable aminopterin analogs with dihydrofolate reductase and the reduced folate carrier as determinants of in vitro antitumor activity

Biochemical Pharmacology

Volumn 65, Issue 9, 2003, Pages 1427-1433

  Wright, Joel E ^a,b   Yurasek, Gregory K ^a   Chen, Ying Nan ^a   Rosowsky, Andre ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Dihydrofolate reductase; N (4 Amino 4 deoxypteroyl) N hemiphthaloyl L ornithine (PT523) and analogs; Reduced folate carrier

Indexed keywords

AMINOPTERIN; AMINOPTERIN DERIVATIVE; CARRIER PROTEIN; DIHYDROFOLATE REDUCTASE; DIHYDROFOLATE REDUCTASE INHIBITOR; DIHYDROFOLIC ACID; EDATREXATE; FOLIC ACID; METHOTREXATE; NALPHA (4 AMINO 4 DEOXYPTEROYL) NDELTA HEMIPHTHALOYLORNITHINE; ORNITHINE DERIVATIVE; RECOMBINANT ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRITIUM;

ANALYTICAL PARAMETERS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CULTURE; CELL GROWTH; CHEMICAL STRUCTURE; COMPETITIVE INHIBITION; DRUG EXPOSURE; DRUG POTENCY; DRUG SCREENING; DRUG TRANSPORT; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LEUKEMIA CELL; MEDICAL LITERATURE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REDUCTION; SPECTROPHOTOMETRY; TIME;

EID: 0038403784     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00102-3     Document Type: Article

References (33)

1. α-(4-amino-4-deoxypteroyl)-L-ornithine derivatives: synthesis and in vitro antitumor activity. J. Med. Chem. 31:1988;1332-1337.
2. δ-hemiphthaloyl-L-ornithine. Pteridines. 1:1989;91-98.
3. Rosowsky A. PT523 and other aminopterin analogs with a hemiphthaloyl-L-ornithine side chain: exceptionally tight-binding inhibitors of dihydrofolate reductase which are transported by the reduced folate carrier but cannot form polyglutamates. Curr. Med. Chem. 6:1999;329-352.
4. Westerhof G.R., Schornagel J.H., Kathman I., Jackman A.L., Rosowsky A., Forsch R.A., Hynes J.B., Boyle F.T., Peters G.J., Pinedo H.M., Jansen G. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. Mol. Pharmacol. 48:1995;459-471.
5. Jansen G., Mauritz R., Drori S., Sprecher H., Kathmann I., Bunni M., Priest D.G., Noordhuis P., Schornagel J.H., Pinedo H.M., Peters G.J., Assaraf Y.G. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J. Biol. Chem. 273:1998;30189-30198.
6. Jansen G., Barr H., Kathmann I., Bunni M.A., Priest D.G., Noordhuis P., Peters G.J., Assaraf Y. Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folypolyglutamylation, expanded folate pools, and intralysosomal drug sequestration. Mol. Pharmacol. 55:1999;761-769.
7. Backus H.H.J., Pinedo H.M., Wouters D., Padrón J.M., Molders N., van der Wilt C.L., van Groeningen C.J., Jansen G., Peters G.J. Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates. Int. J. Cancer. 87:2000;771-778.
8. Zhao R., Gao F., Goldman I.D. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem. Pharmacol. 61:2001;857-865.
9. Li E.W., Lin J.T., Schweitzer B.J., Tong W.P., Niedzwicki D., Bertino J.R. Intrinsic resistance to methotrexate in human soft tissue sarcoma cell lines. Cancer Res. 52:1992;3908-3913.
10. Li W.W., Bertino J.R. Inability of leucovorin to rescue a naturally methotrexate-resistant human soft tissue sarcoma cell line from trimetrexate cytotoxicity. Cancer Res. 52:1992;6866-6870.
11. Gorlick R., Goker E., Tripett T., Waltham M., Banerjee D., Bertino J.R. Intrinsic and acquired resistance to methotrexate in acute leukemia. N. Engl. J. Med. 335:1996;1041-1048.
12. Rosowsky A. Development of nonpolyglutamatable DHFR inhibitors. In: Jackman A, editor. Antifolate drugs in cancer therapy. Totowa: Humana Press; 1999. p. 59-100.
13. ω-hemiphthaloyl-α,ω-diaminoalkanoic acid analogues of aminopterin and 3′,5-dichloroaminopterin. J. Med. Chem. 37:1994;2167-2174.
14. δ-hemiphthaloyl-L-ornithine (PT523) modified in the side chain: synthesis and biological evaluation. J. Med. Chem. 40:1997;286-299.
15. δ-hemiphthaloyl-L-ornithine (PT523). J. Med. Chem. 41:1998;5310-5319.
16. δ-hemiphthaloyl-L-ornithine (PT523) with modifications in the side chain, p-aminobenzoyl moiety, or 9,10-bridge: synthesis and in vitro antitumor activity. J. Med. Chem. 43:2000;1620-1634.
17. δ- hemiphthaloyl-L-ornithine (PT523). J. Med. Chem. 45:2002;1690-1696.
18. δ-hemiphthaloyl-L-ornithine (PT523) and its B-ring analogues. Biochem. Pharmacol. 60:2000;41-46.
19. δ- hemiphthaloyl-L-ornithine. Pharmacol. Ther. 85:2000;191-205.
20. Johnson J.M., Meiering E.M., Wright J.E., Pardo J., Rosowsky A., Wagner G. NMR solution structure of the antitumor compound PT523 and NADPH in the ternary complex with human dihydrofolate reductase. Biochemistry. 36:1997;4399-4411.
21. Cody V., Galitsky N., Luft J.R., Pangborn W., Rosowsky A., Blakley R. Comparison of two independent crystal structures of human dihydrofolate reductase ternary complexes with NADPH and the very tight-binding inhibitor PT523. Biochemistry. 36:1997;13897-13903.
22. McGuire J.J., Bolanowska W.E., Coward J.K., Sherwood R.F., Russell C.A., Felschow D.M. Biochemical and biological properties of methotrexate analogs containing D-glutamic acid or D-erythro,threo-4-fluoroglutamic acid. Biochem. Pharmacol. 42:1991;2400-2403.
23. Piper J.R., Johnson C.A., Maddry J.A., Malik N.D., McGuire J.J., Otter G.M., Sirotnak F.M. Studies on analogues of classical antifolates bearing the naphthoyl group in place of benzoyl in the side chain. J. Med. Chem. 36:1993;4161-4171.
24. DeGraw J.I., Brown V.H., Tagawa H., Kisliuk R.L., Gaumont Y., Sirotnak F.M. Synthesis and antitumor activity of 10-alkyl-10-deazaaminopterins. A convenient synthesis of 10-deazaaminopterin. J. Med. Chem. 25:1982;1227-1230.
25. Laurie S.A., Pfister D.G., Kris M.G., Tong W.P., Chronowski G., Pisters K.M.W., Heelan R.T., Sirotnak F.M. Phase I and pharmacologic study of two schedules of the antifolate edatrexate in combination with cisplatin. Clin. Cancer Res. 7:2001;501-509.
26. DeGraw J.I., Colwell W.T., Piper J.R., Sirotnak F.M. Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin. J. Med. Chem. 36:1993;2228-2231.
27. Krug L.M., Ng K.K., Kris M.G., Miller V.A., Tong W., Heelan R.T., Leon L., Leung D., Kelly J., Sirotnak F.M. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin. Cancer Res. 6:2000;3493-3498.
28. Sirotnak F.M., DeGraw J.I., Colwell W.T., Piper J.R. A new analogue of 10-deazaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother. Pharmacol. 42:1998;313-318.
29. Peterson D.L., Gleisner J.M., Blakley R.M. Bovine liver dihydrofolate reductase: purification and properties of the enzyme. Biochemistry. 14:1975;5261-5267.
30. Johnson S.J., Gupta S.V., Stevenson K.J., Freisheim J.H. Purification and characterization of dihydrofolate reductase from Walker 256 carcinosarcoma. Can. J. Chem. 60:1982;1132-1142.
31. Sierra E.E., Brigle K.E., Spinella M.J., Goldman I.D. pH dependence of methotrexate transport by the reduced folate carrier and the folate receptor in L1210 leukemia cells. Biochem. Pharmacol. 53:1997;223-231.
32. DeGraw J.I., Christie P.H., Tagawa H., Kisliuk R.L., Gaumont Y., Schmid F.A., Sirotnak F.M. Synthesis and biological activity of resolved C-10 diastereomers of 10-methyl- and 10-ethyl-10-deazaaminopterin. J. Med. Chem. 29:1986;1056-1061.
33. Chen Z.S., Lee K., Walther S., Raftogianis R.B., Kuwano M., Zhen H., Krug G.D. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 62:2002;3144-3150.